Skip to Content

A Favorable Safety Profile of IL-23 p19 Inhibitors for Psoriasis

According to dermatologist Andy Blauvelt, the safety of biologics for dermatological diseases such as psoriasis is a significant issue. And he is often asked, ‘’What is the safest one to use?”. New results presented in this MEDtalk indicate a safe and effective profile of IL-23 p19 inhibitors for treating patients with moderate-to-severe plaque psoriasis.

Andy Blauvelt

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top